At least one psilocybin comorbidity trial (PsiloStudy PTSD+AUD or the AUD mechanisms study) will report positive preliminary efficacy signals in a conference presentation before Q1 2027.

Researchers are running trials testing psilocybin on people who have both PTSD and alcohol use disorder at the same time — two conditions that frequently travel together and are notoriously hard to treat. Before early 2027, at least one of these studies is expected to share early results at a scientific conference suggesting psilocybin is helping. Past research on psilocybin and alcohol alone has already looked promising, so these results would extend that pattern.

Preliminary open-label signals for psilocybin in AUD have been strong historically. These pipelines are designed to generate publishable positive early readouts.